Cannara Biotech Inc.
Cannara Biotech Inc. (LOVFF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Cannara Biotech Inc. (LOVFF), featuring income statements, balance sheets, and cash flow data.
Cannara Biotech Inc. (LOVFF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Cannara Biotech Inc. LOVFF financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $26.59M | $25.07M | $23.04M | $19.54M |
| Cost of Revenue | $14.63M | $14.89M | $12.58M | $12.59M |
| Gross Profit | $11.96M | $10.18M | $10.45M | $6.96M |
| Gross Profit Ratio | $0.45 | $0.41 | $0.45 | $0.36 |
| R&D Expenses | $171446.00 | $171689.00 | $241030.00 | $349820.00 |
| SG&A Expenses | $5.63M | $5.49M | $5.07M | $4.85M |
| Operating Expenses | $6.08M | $5.95M | $5.41M | $3.40M |
| Total Costs & Expenses | $20.71M | $20.84M | $17.99M | $15.99M |
| Interest Income | $67763.00 | $61415.00 | $43847.00 | $45313.00 |
| Interest Expense | $1.17M | $1.25M | $1.19M | $1.56M |
| Depreciation & Amortization | $1.64M | $1.55M | $1.77M | $1.51M |
| EBITDA | $7.34M | $5.64M | $5.84M | $5.10M |
| EBITDA Ratio | $0.28 | $0.22 | $0.25 | $0.26 |
| Operating Income | $5.88M | $4.23M | $5.05M | $3.55M |
| Operating Income Ratio | $0.22 | $0.17 | $0.22 | $0.18 |
| Other Income/Expenses (Net) | -$1.15M | -$1.20M | -$1.25M | -$1.53M |
| Income Before Tax | $4.73M | $3.03M | $3.80M | $2.02M |
| Income Before Tax Ratio | $0.18 | $0.12 | $0.16 | $0.10 |
| Income Tax Expense | $1.41M | $728051.00 | -$1.95M | $0.00 |
| Net Income | $3.31M | $2.31M | $5.75M | $2.02M |
| Net Income Ratio | $0.12 | $0.09 | $0.25 | $0.10 |
| EPS | $0.04 | $0.03 | $0.06 | $0.02 |
| Diluted EPS | $0.04 | $0.03 | $0.06 | $0.02 |
| Weighted Avg Shares Outstanding | $90.56M | $90.02M | $90.04M | $90.02M |
| Weighted Avg Shares Outstanding (Diluted) | $92.25M | $91.58M | $91.45M | $91.52M |
Over the past four quarters, Cannara Biotech Inc. demonstrated steady revenue growth, increasing from $19.54M in Q3 2024 to $26.59M in Q2 2025. Operating income reached $5.88M in Q2 2025, maintaining a consistent 22% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $7.34M, reflecting operational efficiency. Net income rose to $3.31M, with EPS at $0.04. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan